Ambulatory blood glucose monitoring and insulin pump are two very important technologies in today’s diabetes treatment. In the past, in clinical practice, only two instruments could be worn separately or simultaneously, and the dose of insulin pump could be adjusted after checking the blood glucose test results. In recent years, with the development of technology, these two technologies have progressed and become more closely integrated. Countries such as the United States have started to use the “Double C” system in the true sense of the word, combining the two into one body. Blood glucose testing is an important prerequisite for diabetic patients to achieve blood glucose control standards. The end-of-finger blood glucose test is now commonly used in clinical practice to help patients obtain blood glucose at any point in time and to help them understand the blood glucose situation at that time and the relationship with their symptoms. Glycosylated hemoglobin (HbA1c) represents the overall blood glucose situation for about 3 months and is an important indicator of whether blood glucose standards are met. In 1999, the world’s first ambulatory glucose monitoring system appeared, and then the ambulatory glucose monitoring technology gradually spread, this retrospective ambulatory glucose monitoring technology is mainly used for the auxiliary diagnosis of diabetic patients, treatment plan formulation, efficacy evaluation, as well as teaching and scientific research. In recent years, the iPro series of retrospective ambulatory glucose monitoring system has significantly reduced the size of the instrument, which is convenient for patients to wear, while using the more advanced and perfect Carelink glucose management software to manage data and reports, making the retrospective ambulatory glucose monitoring more widely used. In recent years, real-time ambulatory glucose monitoring technology has been gradually developed, represented by Medtronic’s Guardian Real-Time. Real-time dynamic blood glucose monitoring can display a blood glucose value every 5 minutes, reflect the information of blood glucose in real time, clearly indicate the pattern and trend of blood glucose changes, and alarm for too high or too low blood glucose, which is more helpful for patients to take timely measures to improve the efficacy of treatment and reduce the risk of hypoglycemia. However, the technology currently used in the clinic is still a subcutaneous probe, which is somewhat different from the technology needed for more frequent determination of blood glucose in the blood that is really expected in the future for a fully intelligent insulin pump. Glucose probe technology determines the accuracy of dynamic blood glucose monitoring, and the intravascular probe has incomparable advantages over the subcutaneous probe. 2010 ADA, several scholars reported the latest progress of the intravascular probe, whether it is the fluorometric probe or the microdialysis probe, which has higher accuracy than the subcutaneous probe. The development of insulin pumps in recent years has focused on the dual-C combination, which is often referred to as SAP (Sensor Augmented Pump). Medtronic’s 722 insulin pump is the world’s first insulin pump that combines real-time dynamic blood glucose monitoring with the function of displaying blood glucose values every 5 minutes, enabling patients to detect changes in blood glucose and make timely adjustments to the insulin pump’s infusion volume and mode. It makes blood glucose more stable and effective to avoid over or under blood glucose. The STAR3 study, published in the New England Journal of Medicine in 2010, which looked at nearly 495 patients with type 1 diabetes for up to one year, confirmed that treatment with Medtronic’s Double C insulin pump could control blood glucose more effectively than multiple subcutaneous insulin injections. Based on SAP, closed-loop pumps are evolving rapidly. 2010 ADA and 2011 ATTD congresses have continued to see the latest advances in closed-loop pumps announced. Current research in closed-loop pumps is focused on nocturnal glycemic control, closed-loop pumps for multiple hormone infusions, etc. The results of several published studies are encouraging, but closed-loop pumps are still in the laboratory stage and are still far from widespread clinical use. The development of double C technology drives the progress of diabetes diagnosis and treatment technology. Double C technology is the basis of the future artificial pancreas and the development direction of comprehensive diabetes management.